Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Nashville, TN
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Houston, TX
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL
Status: Enrolling
Updated:  12/18/2015
Ann & Robert H. Lurie Children's Hospital of Chicago Ann&Robert Lurie
mi
from
Chicago, IL
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL
Status: Enrolling
Updated: 12/18/2015
Ann & Robert H. Lurie Children's Hospital of Chicago Ann&Robert Lurie
mi
from
Chicago, IL
Click here to add this to my saved trials
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL
Status: Enrolling
Updated:  12/18/2015
Novartis Investigative Site
mi
from
Barretos,
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL
Status: Enrolling
Updated: 12/18/2015
Novartis Investigative Site
mi
from
Barretos,
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
Investigative Clinical Research of Indiana
mi
from
Indianapolis, IN
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
Investigative Clinical Research of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
University of Maryland
mi
from
Baltimore, MD
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
Weill-Cornell Medical College
mi
from
New York, NY
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
Mount Sinai Hospital
mi
from
New York, NY
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated:  12/18/2015
VA Puget Sound Health Care System
mi
from
Seattle, WA
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status: Enrolling
Updated: 12/18/2015
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Stanford, CA
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Aurora, CO
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Boston, MA
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Columbus, OH
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Houston, TX
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye
Status: Enrolling
Updated:  12/21/2015
Michigan Cornea Consultants, P.C.
mi
from
Southfield, MI
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye
Status: Enrolling
Updated: 12/21/2015
Michigan Cornea Consultants, P.C.
mi
from
Southfield, MI
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Orange, CA
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
San Diego, CA
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Omaha, NE
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Omaha, NE
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Bronx, NY
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Akron, OH
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Houston, TX
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Orange County Onc Dept
mi
from
Orange, CA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Orange County Onc Dept
mi
from
Orange, CA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Orange County Onc Dept
mi
from
Orange, CA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Orange County Onc Dept
mi
from
Orange, CA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Lurie Children's Hospital of Chicago Onc Dept
mi
from
Chicago, IL
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Lurie Children's Hospital of Chicago Onc Dept
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Lurie Children's Hospital of Chicago Onc Dept
mi
from
Chicago, IL
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Lurie Children's Hospital of Chicago Onc Dept
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital Boston Department of Hematology
mi
from
Boston, MA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital Boston Department of Hematology
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Weill Cornell Medical College-Cornell University Onc Dept
mi
from
New York, NY
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Weill Cornell Medical College-Cornell University Onc Dept
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Weill Cornell Medical College-Cornell University Onc Dept
mi
from
New York, NY
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Weill Cornell Medical College-Cornell University Onc Dept
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Philadelphia Onc. Dept
mi
from
Philadelphia, PA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Philadelphia Onc. Dept
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Children's Hospital of Philadelphia Onc. Dept
mi
from
Philadelphia, PA
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Children's Hospital of Philadelphia Onc. Dept
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated:  12/21/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status: Enrolling
Updated: 12/21/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy
Status: Enrolling
Updated:  12/22/2015
MDACC - Orlando
mi
from
Orlando, FL
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy
Status: Enrolling
Updated: 12/22/2015
MDACC - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy
Status: Enrolling
Updated:  12/22/2015
University of Chicago
mi
from
Chicago, IL
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy
Status: Enrolling
Updated: 12/22/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy
Status: Enrolling
Updated:  12/22/2015
Johns Hopkins University - Bunting Blaustein Cancer Research Building
mi
from
Baltimore, MD
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy
Status: Enrolling
Updated: 12/22/2015
Johns Hopkins University - Bunting Blaustein Cancer Research Building
mi
from
Baltimore, MD
Click here to add this to my saved trials